life sciences  bain capital bain capital investor portal please log in to access your account information if you have any questions regarding your account please contact email protected sign on to your account select an account private equity credit public equity ventures double impact life sciences questions call us  x  global phone support email us email protected search bain capital investor portal please log in to access your account information if you have any questions regarding your account please contact email protected sign on to your account select an account private equity credit public equity ventures double impact life sciences questions call us  x  global phone support email us email protected scaling innovation in life science our team draws on deep industry expertise clinical insights and crossasset class investing experience to drive advances in therapeutics diagnostics and tools to improve the lives of patients with unmet medical needs life sciences about strategy guiding principles portfolio contact us team share this page share this page about life sciences bain capital life sciences invests in biopharmaceutical specialty pharmaceutical medical device diagnostics and enabling life science technology companies globally with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs the differentiated skillset of bain capital’s team enables it to pursue opportunities created by several longterm trends in healthcare in particular these trends are creating an increased need for targeted capital and valueadded strategic support of companies around their critical phases of growth during which they must prove their clinical and business value since  bain capital has employed a strategic analytical approach to identify attractive investment opportunities and partner with management teams to transform and improve their businesses during this time bain capital has developed global reach deep expertise and a proven track record in the life sciences industries across its private equity public equity credit and ventures business units focused strategy across four themes of investments bain capital life sciences targets four types of investment opportunities inflection capital engagement with companies at the critical development stages of innovation growth capital partnering with companies to accelerate and expand platforms fallen angels engaging with companies at a crossroads to create value larger private equity collaborating with the bain capital platform to invest in and support larger companies “bain capital life sciences provides targeted and valueadded support to pursue innovation that improves the lives of patients” guiding principles bain capital life sciences seeks to create differentiated value by identifying investments across a broad spectrum of opportunities targeting companies that drive innovation across the healthcare value chain bringing breakthrough advances to market that improve the lives of patients enabling efficient use of capital through rigorous diligence asset selection and valueadded support portfolio dicerna pharmaceuticals inc solid biosciences contact us for additional information please contact email protected pe quote  bain capital life sciences fund lp  bloomberg markets error could not add to watchlist x  watchlist bain capital life sciences fund lp peus inactive peus is inactive usd fund type private equity fund before its here its on the bloomberg terminal learn more fund type private equity fund objective  asset class focus private equity geographic focus  nav on   total assets  on   inception date  last dividend on   dividend indicated gross yield  fund managers  front load fee  back load fee  redemption fee  b fee  current mgmt fee  expense ratio  profile bain capital life sciences fund lp is a  private equity fund currently investing the fund makes growth investments in the biotechnology  pharmaceuticals health care facilities  services and medical equipment  devices manufacturing industries the fund makes investments globally address  phone  website  bain capital life sciences fund lp  current holdings  fintelio bain capital life sciences fund lp current holdings from f d investorbain capital life sciences fund lp current positions bain capital life sciences fund lp has disclosed  total holdings in their latest sec filings this investor has not filed a f which indicates it has under m in assets under management aum this investor has filed  activist d filings recently which suggests it takes an active role in influencing management bain capital life sciences fund lps top industries are chemicals and allied products sic   overview sec filings dg predictive value all bain capital life sciences fund lp holdings are listed in the following table this data is sourced from dg and f filings green rows indicate new positions red rows indicate closed positions add this fundto your dashboard this is a list of d and g filings made since the last quarterly f report if any file dateformsecurity prevshares currentshares changepercent prev valuex current valuex changepercent ‑‑ sc d drna  dicerna pharmaceuticals inc   fintel ir  find the right investors for your company instantly fintel ir combines the comprehensive fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy learn more now become a power user join our private investing channel request membership bain capital raises  million for life sciences fund  reuters discover thomson reutersfinancialgovernment solutionslegalreuters news agencyrisk management solutionstax  accountingblog answers oninnovation  thomson reutersdirectory of siteslogincontactsupport months agobain capital raises  million for life sciences fundsessionstrumpearningshealthcarecyberriskfutureofmoneyenergyenvironmentsectionsbusinessmarketsworldpoliticstechcommentarybreakingviewsmoneylifepicturesreuters tvdiscover thomson reutersfinancialgovernment solutionslegalreuters news agencyrisk management solutionstax  accountingblog answers oninnovation  thomson reutersdirectory of siteslogincontactsupportfeaturedtrump bans transgender people from military servicetrump bans transgender people from military servicetrump bans transgender people from military servicepicturesreuters tveditionunited statesafricaamérica latinaعربيargentinabrasilcanadadeutschlandespañafranceindiaitaliaméxicoроссияunited kingdomunited statesdealsmay     am   months agobain capital raises  million for life sciences fundcarl odonnell min readreuters  private equity firm bain capital lp said on tuesday it had raised  million for its first investment fund focused exclusively on the life sciences sector the fund will give bain the ammunition to focus on targeted investments at a time when the life sciences industry seeks more capital to fund its expansion we are excited by some of the longterm secular trends in the life sciences space said adam koppel a managing director at bain capital life sciences big pharma is increasingly outsourcing rd at the same time as many new technologies and treatments are being developed guided by a team of eight investment professionals the new business will make investments of between  million and  million in public and private life sciences companies in areas ranging from medical devices to specialty pharmaceuticals to biotech the fund will target companies at several key stages of their life cycle including raising funds for clinical trials scaling up after receiving regulatory approval for their products or pursuing turnarounds it will also partner with bain capitals private equity funds to participate in leveraged buyouts with the exception of its private equity investments the fund will not usually seek a controlling stake in the companies it invests in but it will aim for board representation in its portfolio companies we are not going to be activist investors we are going to be more like what they call constructivist investors who play an important role in companies strategic decisions said jeff schwartz also a managing director at bain capital life sciences bain capital has already made two investments through the new fund in publicly traded biotechnology company dicerna pharmaceuticals inc drnao and in privately held solid biosciences both are developmentstage companies that are aiming to treat rare diseases among other conditions based in boston bain capital is one of the largest alternative investment firms in the world with around  billion of assets under management it has made a number of major investments in various areas of healthcare including contract researcher quintiles behavioral health facility operator acadia healthcare co inc and drugmaker quva pharma reporting by carl odonnell in new york editing by phil berlowitz  narrowbrowserandphonemediumbrowserandportraittabletlandscapetabletmediumwidebrowserwidebrowserandlargermediumbrowserandlandscapetabletmediumwidebrowserandlargerabovephoneportraittabletandaboveaboveportraittabletlandscapetabletandabovelandscapetabletandmediumwidebrowserportraittabletandbelowlandscapetabletandbelowappsnewslettersreuters plusadvertising guidelinescookiesterms of useprivacyall quotes delayed a minimum of  minutes see here for a complete list of exchanges and delays  reuters all rights reserved bain capital launches life sciences fund skip to content finsmes real time vc  private equity deals and news search for facebook twitter linkedin navigation homeusabain capital launches life sciences fund bain capital launches life sciences fund usa published on november  by finsmes global investment firm bain capital has launched its first dedicated life sciences fund according to a regulatory form filed with the sec the vehicle is called bain capital life sciences fund lp the document lists bostonbased managing directors adam m koppel md phd and jeffrey schwartz as people related to the offering whose targeted amount was not disclosed with more than  billion of assets under management bain capital lp is one of the world’s leading private multiasset alternative investment firms founded in  the firm operates in several asset classes including private equity credit public equity and venture capital finsmes  we recommend usa toms receives investment from bain capital by finsmes published on august   usa bain capital to acquire ti automotive by finsmes published on january  january   middle market companiesprivate equitysweden securitas direct acquired by bain capital and hellman  friedman by finsmes published on june   join the discussion cancel replyyou must be logged in to post a comment software for startups video converter from freemake developer the daily deal newsletter – sign up email address signup now to the daily newsletter usa  finsmes skip to content finsmes real time vc  private equity deals and news search for facebook twitter linkedin navigation homeusa usa aiqudo raises m in series a funding acquires sophia aiqudo eyecuedoe a san jose cabased provider of software that lets people use voice commands to execute actions in mobile apps has launched with m in series a funding walkme secures m in funding walkme a san francisco cabased digital adoption platform and software company secured m in funding maniv mobility closes mobility tech venture capital fund at over m maniv mobility lp a tel aviv israelbased venture capital firm dedicated exclusively to mobility tech raised its first fund in excess of m complexa completes m series c funding complexa inc a radnor pabased clinical stage biopharmaceutical company completed a m series c funding rebagg secures m in series b funding rebagg a nycbased luxury goods reseller secured m in series b funding cleo raises £m in seed funding cleo a london ukbased digital ai assistant for managing personal finances raised £m in seed funding ionq completes m series b funding round ionq a college park mdbased developer of quantum computing for commercial applications completed a m series b funding round august home secures m in series c funding august home a san francisco cabased provider of smart locks and smart home access products and services raised m in series c funding gearlaunch raises m in series a funding gearlaunch a san francisco cabased eecommerce platform received m in series a funding signal vine raises m in series a funding signal vine an alexandria vabased enterprise text messaging platform used by higher education institutions to improve student retention and persistence secured m in series a funding signature medical completes m series a funding round signature medical inc a boston mabased digital healthcare company completed a m series a funding round naveego secures k funding round naveego a traverse city mibased provider of cloudbased data quality and master data management mdm solutions secured k in funding monroe capital provides m assetbased facility to betteridge jewelers betteridge jewelers inc a greenwich connecticutbased premier jeweler and watch retailer received a m assetbased facility grabr raises m in funding grabr a san francisco cabased platform introducing a way for shoppers to access international goods raised m in funding rodeo therapeutics raises m in series a funding rodeo therapeutics a seattle wabased company developing smallmolecule therapies designed to promote regeneration and repair of multiple tissue types raised m in series a financing software for startups video converter from freemake developer the daily deal newsletter – sign up email address signup now to the daily newsletter bain capital life sciences fund private company information  bloomberg july    pm et capital markets company overview of bain capital life sciences fund snapshot people company overview bain capital life sciences fund specializes in buyouts inflection capital growth capital turnaround and private equity investments it seeks to invest in life sciences sector with a focus on biopharmaceutical specialty pharmaceutical medical device diagnostics and enabling life science technology companies globally it seeks to make investments between  million and  million it prefers to take a majority stake and a board seat in its portfolio companies john hancock tower clarendon streetboston ma united statesfounded in  phone  fax  key executives for bain capital life sciences fund mr jeffrey lawrence schwartz managing director age  dr adam m koppel mba md phd managing director age  mr ricky sun principal ms orly mishan principal dr jeffrey p green md partner compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement march   dicerna pharmaceuticals inc private placement march   solid biosciences llc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact bain capital life sciences fund please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close bain capital raises  million for life sciences fund reuters  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital bain capital raises  million for life sciences fund reuters may   by reuters news print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub bain capital raises  million for life sciences fund reuters private equity firm bain capital lp said on tuesday it had raised  million for its first investment fund focused exclusively on the life sciences sector reuters reported continue reading on pe hub writes reuters — private equity firm bain capital lp said on tuesday it had raised  million for its first investment fund focused exclusively on the life sciences sector the fund will give bain the ammunition to focus on targeted investments at a time when the life sciences industry seeks more capital to fund its expansion “we are excited by some of the longterm secular trends in the life sciences space” said adam koppel a managing director at bain capital life sciences “big pharma is increasingly outsourcing rd at the same time as many new technologies and treatments are being developed” guided by a team of eight investment professionals the new business will make investments of between  million and  million in public and private life sciences companies in areas ranging from medical devices to specialty pharmaceuticals to biotech the fund will target companies at several key stages of their life cycle including raising funds for clinical trials scaling up after receiving regulatory approval for their products or pursuing turnarounds it will also partner with bain capital’s private equity funds to participate in leveraged buyouts with the exception of its private equity investments the fund will not usually seek a controlling stake in the companies it invests in but it will aim for board representation in its portfolio companies “we are not going to be activist investors we are going to be more like what they call ‘constructivist’ investors who play an important role in companies’ strategic decisions” said jeff schwartz also a managing director at bain capital life sciences bain capital has already made two investments through the new fund in publicly traded biotechnology company dicerna pharmaceuticals inc drnao and in privately held solid biosciences both are developmentstage companies that are aiming to treat rare diseases among other conditions based in boston bain capital is one of the largest alternative investment firms in the world with around  billion of assets under management it has made a number of major investments in various areas of healthcare including contract researcher quintiles behavioral health facility operator acadia healthcare co inc and drugmaker quva pharma print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub bain capital raises  million for life sciences fund reuters private equity firm bain capital lp said on tuesday it had raised  million for its first investment fund focused exclusively on the life sciences sector reuters reported continue reading on pe hub writes dont miss out meet new and diverse managers in private equity venture capital and real estate at the third emerging manager connect east at new york citys harvard club click here for details sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian bain capital double impact funds two companies by iris dorbian midocean to sell water pik for  bln by luisa beltran kkr to buy nature’s bounty from carlyle by luisa beltran carlyle to invest in zerochaos by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian awake security nabs over  mln from greylock and bain capital ventures by iris dorbian the pe hub podcast episode two by staff report secgems bain capital life sciences fund lp data feeds now available excel  csv  java  python etc database learn more bain capital life sciences fund lp info ownership filings  ←  → filings    of   total  april    issuer dicerna pharmaceuticals inc drna reporting owner bain capital life sciences investors llc   owner  bain capital life sciences partners lp   owner  bain capital life sciences fund lp   owner  bcip life sciences associates lp   owner  schwartz jeffrey lawrence   owner  koppel adam   owner director  signed by bain capital life sciences investors llc by adam koppel name adam koppel title managing director bain capital life sciences partners lp by bain capital life sciences investors llc its general partner by adam koppel name adam koppel title managing director bain capital life sciences fund lp by bain capital life sciences partners lp its general partner by bain capital life sciences investors llc its general partner by adam koppel name adam koppel title managing director bcip life sciences associates lp by boylston coinvestors llc its general partner by adam koppel name adam koppel title authorized signatory jeffrey schwartz adam koppel preview view filing   nc xml  ownership initial statement of beneficial ownership of securities insider trading  directors officers significant shareholders  period ending april   redeemable convertible preferred stock  see footnotes   underlying securities common stock   shares april    filed by bain capital life sciences fund lp subject company dicerna pharmaceuticals inc group member bcip life sciences associates lp preview view filing  sc d nc acquisition of beneficial ownership of  or more of any class of equity securities includes buy  acquire  sell  dispose  or more incl takeovers change of control nov    filer bain capital life sciences fund lp form d persons adam koppel jeffrey schwartz signed by sean m doherty preview view filing  d nc xml  notice of exempt offering of securities  made without registration  regulation d and section  small businesses  item b federal exemptions and exclusions rule b c federal exemptions and exclusions investment company act section c c federal exemptions and exclusions investment company act section c primary issuer bain capital life sciences fund lp  other cayman islands exempted limited partnership jurisdiction cayman islands related persons adam koppel  executive officer  jeffrey schwartz  executive officer  industry pooled investment fund private equity fund offering data revenue range decline to disclose date of first sale yet to occur  pooled investment fund  total offer  indefinite total sold   total remaining  indefinite  investors  investors have already invested in this offering db bain capital high income research report  revenue  market share  competition  growth target new business track competition subscribe log in solutions for investment bankingmarket researchprivate equityexecutivesconsultantsreporters  journalists   ✕ log in email address password ✕ subscribe email address password bain capital high income premium company report the premium bain capital high income company report contains critical information including revenue from previous years  growth rate estimated financials and profit margin funding from venture capital and private equity firms latest trademark applications additional industries in which the company operates  view subscription options dba bain capital llcdba bain capital asia fund ii lpdba bain capital double impact fund lpdba bain capital fund xi lpdba bain capital life sciences fund lpdba bain capital public equity global industrials fund lpdba bain capital structured credit feeder lpdba bain capital structured credit fund lpdba bain capital venture fund  lp clarendon street boston ma  company awards big fish vc  private equity company profile  financial information for bain capital high income bain capital high incomes revenue profitability growth rate by year trademarks and applications show bain capital high incomes marketing strategy precise revenue figures by year number of employees and trademarks indicate bain capital high incomes strengths bain capital high income operates in the na industry a list of fastest growing competitors and info on recession risks show bain capital high incomes weaknesses relative to its competitors access the complete profile fast facts revenueover  million    exact revenue in premium reportemployees  exact employee count available in premium reportprimary industry na note revenues are statistical evaluations bain capital high incomes business operations profile shows critical firmographic facts what is the companys size revenue and employees what industry is the company in bain capital high income revenue and growth rate bain capital high income revenue  mmgrowth rate  employees details in premium report    year growth rateyear growth rate cagr investor activity bain capital high income has actively raised capital from investors these investors may include private investors venture capital firms or other investment vehicles date investors percent raised target size june    inf  mm complete list of funding rounds and total amounts in the company report income statement industry averages bain capital high incomes income statement based on industry averages  millionsindustry average total revenue operating revenue cost of goods sold gross profit operating expenses pension profit sharing plans stock annuity repairs rent paid on business property charitable contributions depletion domestic production activities deduction advertising compensation of officers salaries and wages employee benefit programs taxes and licenses bad debts depreciation amortization other operating expenses total operating expenses operating income nonoperating income ebitda ebit earnings before interest and taxes interest expense earnings before taxes income tax net profit   trademark applications trademark applications moreso than trademark registrations show the products and services that are developing and being actively marketed companies that dont have any trademark applications are more likely to be stable maintaining their existing business lines companies that are applying for new trademarks are likely to be investing in rd and marketing attempting to expand more rapidly or pivoting to reach strategic markets trademarks may include brand names product names logos and slogans trademark date committed to lasting impactfinancial services namely investment advice investment management investment consultation and investment of funds for others  see all trademarks in the full report recession risk incfact analyzed data from the last recession to determine whether bain capital high income grew or shrank over that period we also looked at other companies in the industry to compare how recessionproof bain capital high income is relative to the industry while a new recession may strike a particular industry measuring the industry and companys robustness during the last recession estimates its ability to weather future recessions market share of competition bain capital high income vs largest competitors a competitive analysis shows these companies are in the same general field as bain capital high income even though they may not compete headtohead these are the largest companies by revenue however they may not have the largest market share in this industry if they have diversified into other business lines the competition section of a business plan or investment memorandum would start by analyzing the information about these companies competitive advantage comes from offering better pricing or superior productsservice company headquartersrevenue  mmnearby competitioninfo on companies that are located in close proximity to bain capital high income operating in similar markets while some companies particularly retail compete with neighboring businesses for customers other companies may compete to attract skilled employees bain capital high incomes competitorsrevenue  mm fastest growing competitorsthese companies are in the same general field as bain capital high income and are rapidly expanding companies may grow organically or through acquisition in some cases apparently high growth rates may be caused by data that werent available in previous years companyrevenue  mm   discover  incfact contact us press  media terms of use privacy policy  s   incfactcom all rights reserved